S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

• M Telen,
• S Saraf,
• K Cruz,
• M Idowu,
• T Kalfa,
• I Osunkwo,
• R Hagar,
• J Geib,
• S Forsyth,
• P Schroeder,
• E Wu,
• P Kelly,
• R Brown

Affiliations

M Telen

1 Duke University, Durham, UNITED STATES

S Saraf

2 University of Illinois, Chicago, UNITED STATES

K Cruz

3 Advanced Pharma, Miami, UNITED STATES

M Idowu

4 Memorial Hermann-Texas Medical Center, Houston, UNITED STATES

T Kalfa

5 Cincinnati Children’s Hospital Medical Center, Cincinnati, UNITED STATES

I Osunkwo

6 Levine Cancer Institute, Atrium Health, Charlotte, UNITED STATES

R Hagar

7 UCSF Benioff Children’s Hospital San Francisco, Oakland, UNITED STATES

J Geib

8 Forma Therapeutics, Inc, Watertown, UNITED STATES

S Forsyth

8 Forma Therapeutics, Inc, Watertown, UNITED STATES

P Schroeder

8 Forma Therapeutics, Inc, Watertown, UNITED STATES

E Wu

8 Forma Therapeutics, Inc, Watertown, UNITED STATES

P Kelly

8 Forma Therapeutics, Inc, Watertown, UNITED STATES

R Brown

9 Children’s Healthcare of Atlanta, Atlanta, UNITED STATES